TBK1 and hepatocellular carcinoma: Tiliroside hindered the development of HepG2 tumors in both subcutaneous and orthotopic xenograft tumor models of HCC which further enhanced the effectiveness of sorafenib in treating hepatocellular carcinoma by targeting TBK1 to trigger ferroptosis (Yang et al., 2023).